Canada Plans To Force Firms To Disclose Confidential Pricing Deals
Executive Summary
Companies operating in Canada could face pharmacoeconomic evaluations to decide if drugs are over-priced as well as a requirement to disclose information that could impair the confidentiality of pricing agreements.
You may also be interested in...
Some Drug Prices Could Drop 40% Under Canada’s Cost Lowering Proposals
The prices of patented medicines overall are expected to go down in Canada under new proposed regulatory amendments.
Hep C And Other High-Cost Drugs Behind 10% Rise In Canadian Medicines Spend
Public drug plan spending on medicines in Canada rose by nearly 10% in 2015-16, driven by a shift to the use of expensive patented drugs such as the direct acting antivirals for hepatitis C.
Canada Plans Drug Price Reductions By Changing Reference Country List
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.